ロード中...
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT). However, its safety and efficacy in preventing acute GVHD in setting...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639486/ https://ncbi.nlm.nih.gov/pubmed/28784598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-790469 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|